etranacogene dezaparvovec hemophilia B
Selected indexed studies
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. (N Engl J Med, 2023) [PMID:36812434]
- Etranacogene dezaparvovec for hemophilia B gene therapy. (Ther Adv Rare Dis, 2021) [PMID:37181105]
- Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). (Expert Opin Biol Ther, 2023) [PMID:37962325]
_Worker-drafted node — pending editorial review._
Connections
etranacogene dezaparvovec hemophilia B is a side effect of
Sources
- Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. (2023) pubmed
- Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). (2023) pubmed
- Gene therapy for hemophilia. (2022) pubmed
- Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. (2024) pubmed
- Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. (2025) pubmed
- Etranacogene dezaparvovec for hemophilia B gene therapy. (2021) pubmed
- Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. (2024) pubmed
- Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. (2026) pubmed
- PMID:39466920 (2024) pubmed
- Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B. (2023) pubmed